373 related articles for article (PubMed ID: 24404143)
1. Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2.
Wang W; Yan J; Wang H; Shi M; Zhang M; Yang W; Peng C; Li H
PLoS One; 2014; 9(1):e83908. PubMed ID: 24404143
[TBL] [Abstract][Full Text] [Related]
2. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin Attenuates Splenomegaly in both Intrahepatic and Prehepatic Portal Hypertensive Rats by Blocking mTOR Signaling Pathway.
Chen Y; Wang W; Wang H; Li Y; Shi M; Li H; Yan J
PLoS One; 2016; 11(1):e0141159. PubMed ID: 26734934
[TBL] [Abstract][Full Text] [Related]
4. Effect of sirolimus on liver cirrhosis and hepatic encephalopathy of common bile duct-ligated rats.
Wu KC; Huang HC; Chang T; Lee WS; Chuang CL; Hsin IF; Hsu SJ; Lee FY; Chang CC; Lee SD
Eur J Pharmacol; 2018 Apr; 824():133-139. PubMed ID: 29444470
[TBL] [Abstract][Full Text] [Related]
5. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
[TBL] [Abstract][Full Text] [Related]
6. Selective interference of mTORC1/RAPTOR protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism with Akt and autophagy induction.
Ito M; Yurube T; Kakutani K; Maeno K; Takada T; Terashima Y; Kakiuchi Y; Takeoka Y; Miyazaki S; Kuroda R; Nishida K
Osteoarthritis Cartilage; 2017 Dec; 25(12):2134-2146. PubMed ID: 28888905
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension.
Houssaini A; Abid S; Mouraret N; Wan F; Rideau D; Saker M; Marcos E; Tissot CM; Dubois-Randé JL; Amsellem V; Adnot S
Am J Respir Cell Mol Biol; 2013 May; 48(5):568-77. PubMed ID: 23470622
[TBL] [Abstract][Full Text] [Related]
8. Ethyl Acetate Fraction of Dicliptera chinensis (L.) Juss. Ameliorates Liver Fibrosis by Inducing Autophagy via PI3K/AKT/mTOR/p70S6K Signaling Pathway.
Liu Y; Bi YM; Pan T; Zeng T; Mo C; Sun B; Gao L; Lyu ZP
Chin J Integr Med; 2022 Jan; 28(1):60-68. PubMed ID: 34105096
[TBL] [Abstract][Full Text] [Related]
9. Vascular tumors have increased p70 S6-kinase activation and are inhibited by topical rapamycin.
Du W; Gerald D; Perruzzi CA; Rodriguez-Waitkus P; Enayati L; Krishnan B; Edmonds J; Hochman ML; Lev DC; Phung TL
Lab Invest; 2013 Oct; 93(10):1115-27. PubMed ID: 23938603
[TBL] [Abstract][Full Text] [Related]
10. Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension.
Mejias M; Garcia-Pras E; Gallego J; Mendez R; Bosch J; Fernandez M
J Hepatol; 2010 Apr; 52(4):529-39. PubMed ID: 20206401
[TBL] [Abstract][Full Text] [Related]
11. Comparison of anti-peritoneal fibrotic effects between an mTORC1-specific blocker and a PI3K/mTOR dual-blocker.
Xu T; Lin T; Xie J; Ren H; Chen N; Wang W
Ren Fail; 2019 Nov; 41(1):267-277. PubMed ID: 30982374
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological inhibition of mTORC1 but not mTORC2 protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism through Akt and autophagy induction.
Kakiuchi Y; Yurube T; Kakutani K; Takada T; Ito M; Takeoka Y; Kanda Y; Miyazaki S; Kuroda R; Nishida K
Osteoarthritis Cartilage; 2019 Jun; 27(6):965-976. PubMed ID: 30716534
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms.
Biecker E; De Gottardi A; Neef M; Unternährer M; Schneider V; Ledermann M; Sägesser H; Shaw S; Reichen J
J Pharmacol Exp Ther; 2005 Jun; 313(3):952-61. PubMed ID: 15769867
[TBL] [Abstract][Full Text] [Related]
14. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P
United European Gastroenterol J; 2020 Dec; 8(10):1174-1185. PubMed ID: 32878579
[TBL] [Abstract][Full Text] [Related]
15. The anti-fibrotic effects of epigallocatechin-3-gallate in bile duct-ligated cholestatic rats and human hepatic stellate LX-2 cells are mediated by the PI3K/Akt/Smad pathway.
Yu DK; Zhang CX; Zhao SS; Zhang SH; Zhang H; Cai SY; Shao RG; He HW
Acta Pharmacol Sin; 2015 Apr; 36(4):473-82. PubMed ID: 25832428
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
17. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation.
Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN
J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732
[TBL] [Abstract][Full Text] [Related]
19. ERK1/2-dependent activation of mTOR/mTORC1/p70S6K regulates thrombin-induced RPE cell proliferation.
Parrales A; López E; Lee-Rivera I; López-Colomé AM
Cell Signal; 2013 Apr; 25(4):829-38. PubMed ID: 23291002
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin prevents cadmium-induced neuronal cell death via targeting both mTORC1 and mTORC2 pathways.
Xu C; Liu C; Liu L; Zhang R; Zhang H; Chen S; Luo Y; Chen L; Huang S
Neuropharmacology; 2015 Oct; 97():35-45. PubMed ID: 26002629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
